Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

The Fall Of Pfizergan: The Beginning, The End And Everything In Between

Executive Summary

The $160bn mega-merger that never came to be was exciting to watch unfold from beginning to the stunning end, when it was derailed by the US government. “The Pink Sheet” followed every twist and turn along the way.

Advertisement

Related Content

Consumer Business An Asset To Pfizer, A Divestment Chip To Analysts
US Treasury’s Final Earnings Stripping Guidance Keeps Pressure On Inversions
Big Pharma’s Unlikely Price Pledge Leader

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel